Completed NA INTERVENTIONAL 4-arm NCT05242718

Immune Diversity Response to Oral Dosing of Nutritional Health Products in Healthy Participants

A Open Label, Multi-Dose, Multi-Period Exploratory Clinical Trial to Test Immune Diversity Response to Oral Dosing of Approved Nutritional Health Products at Approved Doses to Healthy Volunteers

Sponsor: Dicentra Inc.

Conditions Immunity Disorders

Interventions Curcumin Echinacea purpurea N-Acetyl-L-cysteine (NAC) Palmitoylethanolamide

Updated 3 times since 2022 Last updated: Feb 7, 2022 Started: Jan 10, 2021 Primary completion: May 1, 2021 Completion: May 20, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05242718, this NA trial focuses on Immunity Disorders and remains completed. Sponsored by Dicentra Inc., it has been updated 3 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Mar 2022 — Jul 2024 [monthly]

Completed NA

First recorded

Jan 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dicentra Inc.
Immunoflex Therapeutics Inc.
University of British Columbia

Data source: Immunoflex Therapeutics Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada